Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI SWOT - About
Sunshine Biopharma Inc. Warrant (SBFMW)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
07/08/2025: SBFMW (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
0 Analysts rated it
Very few follow this stock; limited insights, higher-risk early investing.
Analysis of Past Performance
Type Stock | Historic Profit -100% | Avg. Invested days 18 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  1.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 07/08/2025 |
Key Highlights
Company Size ETF | Market Capitalization 0 USD | Price to earnings Ratio - | 1Y Target Price - |
Price to earnings Ratio - | 1Y Target Price - | ||
Volume (30-day avg) - | Beta 0.96 | 52 Weeks Range 0.05 - 0.98 | Updated Date 05/25/2025 |
52 Weeks Range 0.05 - 0.98 | Updated Date 05/25/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -2.21 |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin -13.88% | Operating Margin (TTM) -14.56% |
Management Effectiveness
Return on Assets (TTM) -11.78% | Return on Equity (TTM) -21.17% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value - | Price to Sales(TTM) - |
Enterprise Value - | Price to Sales(TTM) - | ||
Enterprise Value to Revenue - | Enterprise Value to EBITDA - | Shares Outstanding - | Shares Floating 4553895 |
Shares Outstanding - | Shares Floating 4553895 | ||
Percent Insiders - | Percent Institutions - |
Upturn AI SWOT
Sunshine Biopharma Inc. Warrant
Company Overview
History and Background
Sunshine Biopharma Inc. is focused on the research and development of oncology and antiviral drugs. The warrant is a derivative security linked to the underlying common stock. The warrant details are dependent on the warrant offering and should be specifically referenced from the warrant prospectus.
Core Business Areas
- Pharmaceutical Research and Development: Focus on developing therapeutics for oncology and antiviral applications.
- Drug Commercialization: Bringing developed drugs to market, typically through partnerships or direct sales.
Leadership and Structure
The leadership team typically includes a CEO, CSO, and CFO. The organizational structure is likely hierarchical with departments focused on research, development, and administration.
Top Products and Market Share
Key Offerings
- Adva-27a: A small molecule compound being developed for the treatment of various cancers. It is in preclinical or early clinical stages. Market share is currently negligible as the product is not yet commercialized. Competitors include established cancer therapies and companies developing similar novel oncology drugs.
- mRNA-based therapeutics: Developing mRNA-based therapies, potentially for cancer or other diseases. Market share is negligible as the product is pre-commercial. Competitors are established players like Moderna and BioNTech in the mRNA space.
Market Dynamics
Industry Overview
The pharmaceutical industry is highly competitive and regulated. Significant investment is required for research and development. Cancer and antiviral drug markets are substantial and growing.
Positioning
Sunshine Biopharma is a small player in the pharmaceutical industry, focused on niche areas of oncology and antiviral research. Its competitive advantage lies in its proprietary drug candidates. The TAM is large, but Sunshine Biopharma currently captures a very small portion due to its development stage.
Total Addressable Market (TAM)
The global oncology and antiviral drug markets are worth hundreds of billions of dollars. Sunshine Biopharma aims to capture a portion of this market. It is positioned as a research company.
Upturn SWOT Analysis
Strengths
- Proprietary drug candidates
- Focus on specific therapeutic areas
- Potential for breakthrough therapies
Weaknesses
- Limited financial resources
- Early-stage development pipeline
- Dependence on partnerships for commercialization
Opportunities
- Partnerships with larger pharmaceutical companies
- Successful clinical trial outcomes
- Expansion into new therapeutic areas
Threats
- Clinical trial failures
- Regulatory hurdles
- Competition from established players
- Funding challenges
Competitors and Market Share
Key Competitors
- MRNA
- PFE
- JNJ
- GILD
Competitive Landscape
Sunshine Biopharma operates in a highly competitive landscape dominated by larger, well-established pharmaceutical companies. It must rely on innovation and strategic partnerships to compete effectively.
Growth Trajectory and Initiatives
Historical Growth: Historical growth has been limited due to its research-focused nature.
Future Projections: Future growth depends on successful clinical trials and commercialization of its drug candidates. Analyst estimates are needed to forecast future revenue and earnings.
Recent Initiatives: Recent initiatives may include clinical trial advancements, partnerships, and fundraising activities.
Summary
Sunshine Biopharma is a small, early-stage pharmaceutical company focused on oncology and antiviral research. Its strengths lie in its proprietary drug candidates, but it faces challenges due to limited resources and competition. Successful clinical trials and strategic partnerships are crucial for its future growth.The warrants' value is tied to the underlying common stock, so it is important to understand the risks and opportunities surrounding the company.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company SEC filings
- Company website
- Third-party financial analysis reports
Disclaimers:
The information provided is for informational purposes only and should not be considered investment advice. Investment decisions should be based on your own research and due diligence.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Sunshine Biopharma Inc. Warrant
Exchange NASDAQ | Headquaters Fort Lauderdale, FL, United States | ||
IPO Launch date 2022-02-15 | Chairman, President & CEO Dr. Steve N. Slilaty Ph.D. | ||
Sector Healthcare | Industry Drug Manufacturers - Specialty & Generic | Full time employees 52 | Website https://sunshinebiopharma.com |
Full time employees 52 | Website https://sunshinebiopharma.com | ||
Sunshine Biopharma, Inc. operates as a pharmaceutical company that focuses on the research and development of life-saving medicines in various therapeutic areas, including oncology and antivirals in the United States and Canada. It operates through Prescription Generic Pharmaceuticals and Nonprescription Over-The-Counter Products segments. The company is developing SBFM-PL4, a protease inhibitor for the treatment of SARS coronavirus infections; Adva-27a, a small chemotherapy molecule to treat pancreatic cancer; and K1.1 mRNA, a lipid nano-particle for liver cancer. It also offers Essential 9, an amino acids capsules; Calcium-Vitamin D supplement under the Essential Calcium-Vitamin D brand name; and L-Citrulline and Taurine products. In addition, the company provides various generic prescription drugs for osteoporosis, cardiovascular, antipsychotic, antibacterial, hypertension, anti-inflammatory, allergy, antibiotic, central nervous system, diabetes, urology, antifungal, antimalarial, oncology, gastroenterology, and anticonvulsant indications. Sunshine The company is based in Fort Lauderdale, Florida.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.